Table 4.
Stock levels of test kits, lancets, drugs and needles and syringes for HIV and syphilis testing and treatment
| Consumables | Stock levels | ||
|---|---|---|---|
| Nil | < 1 month | ≥1 month | |
| Test kits and lancets | |||
| Syphilis test kits (n = 13)a | 6 | 0 | 7 |
| Syphilis test kits-chase buffer (n = 13)a | 6 | 1 | 6 |
| HIV test kits/diluent (n = 14)b | 0 | 4 | 10 |
| Lancets (n = 15) | 1 | 0 | 14 |
| Drugs and needles and syringes | |||
| Injection Benzathine penicillin (n = 13)a | 8 | 1 | 6 |
| Tablets Erythromycin (n = 13)a | 7 | 0 | 8 |
| Syrup Nevirapine (n = 8)c | 0 | 2 | 6 |
| Tablets Sulphadoxine pyrimethamine (n = 15) | 2 | 1 | 12 |
| Needles and syringes (n = 15) | 1 | 0 | 14 |
a2 facilities which had not started syphilis screening were excluded; b1 facility which had not started antenatal HIV screening was excluded; c7 facilities that were not offering antiretroviral therapy (nevirapine) to babies of HIV positive mothers and referred all babies to other facilities for treatment were excluded